BusinessArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 25, 2016, 12:31 PM UTC
